Skip to content
by Legal Desire
12 February 2021

Latham & Watkins Advises the Underwriters in Talis Biomedical’s Initial Public Offering

Advising firms

Deal team

14 lawyers named
LawyerFirmSeniorityPracticeOffice
Brian Cuneo Lead Latham & Watkins LLP Partner corporate Bay Area
Miles Jennings Lead Latham & Watkins LLP Partner corporate Bay Area
Ken Hagan Latham & Watkins LLP Associate corporate Not stated
Raul Gonzalez Latham & Watkins LLP Associate corporate Not stated
John Manthei Latham & Watkins LLP Partner FDA regulatory Washington, D.C.
Elizabeth Richards Latham & Watkins LLP Partner FDA regulatory Washington, D.C.
Heather Deixler Latham & Watkins LLP Counsel FDA regulatory Bay Area
Betty Pang Latham & Watkins LLP Counsel FDA regulatory Bay Area
Barrett Tenbarge Latham & Watkins LLP Associate FDA regulatory Not stated
Chris Hazuka Latham & Watkins LLP Partner intellectual property Bay Area
Brendan Haberle Latham & Watkins LLP Associate intellectual property Not stated
Ashley Wagner Latham & Watkins LLP Partner benefits and compensation Bay Area
Grace Lee Latham & Watkins LLP Partner tax Bay Area
Amy Feinberg Latham & Watkins LLP Associate tax Not stated

Stated terms

Stated value
USD 221m (US$220.8 million)
What the figure measures
Issue size
Client
Latham & Watkins LLPUnderwriters
Counterparties
Talis Biomedical Corporation (Issuer)